Mr. Goldberg is an Advisor to Torreya Partners (www.torreya.com), a leading boutique advisory firm based in New York and London that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and, as well as Advises several $1 billion + private equity funds, including Riverside Partners (www.riverside partners.com) and DRI Capital (www.dricapital.com), and serves on several private company board of directors . He has over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. He has been an operating executive in a $1 billion + sales pharmaceutical company, a partner in a venture capital fund, and an entrepreneurial founder of several companies that were later acquired.Mr. Goldberg served as Managing Director, Corporate Development for Endo Pharmaceuticals (Nasdaq: ENDP), a leading pain therapeutics company, from 2003-2008. In this position, Mr. Goldberg was responsible for Endo’s overall corporate development activities, including structuring, negotiating and closing transactions such as the acquisitions of companies , products and product lines. Prior to Endo, he was a founding partner of ProQuest Investments from 1997-2002, the first cancer-focused venture capital fund, where he and partners raised over $250 MM in Funds I, II to acquire positions in biotechnology, specialty pharmaceutical, and medical device companies. Representative investments or deals sourced include Conforma Therapeutics (acquired by Biogen IDEC), Threshold Pharmaceuticals, and Pharmion (acquired by Celgene).Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer for $1.9 billion, as well as operating positions at SmithKline (now Glaxo SmithKline) and Becton Dickinson.
Mr. Goldberg is a magna cum laude graduate of Harvard College and Harvard Business School. He serves on the Visiting Committee for Solid Tumour Oncology at Dana Farber Cancer Institute and on the board of the International Research Alliance, a private sector philanthropy supporting NIH and Oxford and Cambridge University, as well as on the board of private companies Cell Signaling Technology, Dominion Diagnostics. Mr. Goldberg has also served as an advisor to a private Healthcare IT company, Clear Cost Health, that provides price transparency services to customers including Starbucks. He has been an invited speaker at the University of Pennsylvania Wharton/Windhover program for Pharmaceutical executives, Harvard Business School, and served as moderator for over 10 years for Communitech’s Cancer Progress conference.